Only half of white elderly women and 40% of black elderly women with non-metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer receive appropriate monoclonal antibody therapy [17]. This evidence concerns the gene ERBB2 and breast carcinoma.